Equity · Healthcare
BIOA
NASDAQBioAge Labs (BIOA)
The line runs 9.38 USD on 24 August through 4.28 USD on 20 November, on a scale from 4 to 12. Days the market did not trade hold the previous close, flat.
- Market cap
- 196.7M USD
- Revenue, year to Dec 2025
- 9.0M USD
- EPS, diluted, year to Dec 2025
- −2.24 USD
- Avg volume
- 43.4K
as of Nov 20, 2026
Have BioAge Labs (BIOA) insiders bought or sold shares recently?
BIOA's newest Form 4 filing is dated 30 June 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Jun 2026 | Barton ShanePrincipal Accounting Officer | Sell | 20,216 | 509K USD |
| 29 Jun 2026 | Barton ShanePrincipal Accounting Officer | Sell | 42,350 | 1.1M USD |
| 01 Apr 2026 | RUBIN PAUL DChief Medical Officer | Sell | 8,820 | 157K USD |
| 02 Mar 2026 | RUBIN PAUL DChief Medical Officer | Sell | 7,433 | 151K USD |
| 02 Feb 2026 | RUBIN PAUL DChief Medical Officer | Sell | 7,433 | 139K USD |
| 13 Jan 2026 | GOLDSTEIN DOV A MDChief Financial Officer | Sell | 27,000 | 532K USD |
| 13 Jan 2026 | Fortney KristenChief Executive Officer | Sell | 233,107 | 4.2M USD |
| 02 Jan 2026 | RUBIN PAUL DChief Medical Officer | Sell | 7,433 | 95K USD |
| 09 Dec 2025 | RUBIN PAUL DChief Medical Officer | Sell | 18,000 | 216K USD |
| 04 Dec 2025 | RUBIN PAUL DChief Medical Officer | Sell | 68,897 | 702K USD |
| Sold | 10 open-market sales | 440,689 | $7.79M |
13 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Jun 2026 | Barton ShanePrincipal Accounting Officer | Option exercise | 20,216 | 132K USD |
| 29 Jun 2026 | Barton ShanePrincipal Accounting Officer | Option exercise | 39,718 | 263K USD |
| 23 Apr 2026 | GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | 3,542 | 16K USD |
| 01 Apr 2026 | RUBIN PAUL DChief Medical Officer | Option exercise | 8,820 | 45K USD |
| 02 Mar 2026 | RUBIN PAUL DChief Medical Officer | Option exercise | 7,433 | 35K USD |
| 01 Mar 2026 | GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | 3,542 | 16K USD |
| 02 Feb 2026 | RUBIN PAUL DChief Medical Officer | Option exercise | 7,433 | 35K USD |
| 01 Feb 2026 | GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | 3,541 | 16K USD |
| 16 Jan 2026 | GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | 3,542 | 16K USD |
| 13 Jan 2026 | GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | 27,000 | 227K USD |
| 02 Jan 2026 | RUBIN PAUL DChief Medical Officer | Option exercise | 7,433 | 35K USD |
| 09 Dec 2025 | RUBIN PAUL DChief Medical Officer | Option exercise | 18,000 | 118K USD |
Showing the 12 most recent of 13 compensation filings in this window. The figures above count all of them.
Which funds hold BioAge Labs (BIOA)?
8 of the 45 institutional funds we track reported a BioAge Labs position for the quarter ended 30 Sep 2026 — a combined 21.4M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| D. E. Shaw & Co. | Added | 1,156,404 | 8.2M USD | +55.7% |
| Millennium Management | Added | 636,546 | 4.5M USD | +185.9% |
| Renaissance Technologies | Added | 626,661 | 4.4M USD | +278.2% |
| Two Sigma Investments | Added | 221,714 | 1.6M USD | +261.1% |
| AQR Capital Management | Added | 182,378 | 1.3M USD | +256.3% |
| Man Group | Added | 127,103 | 901K USD | +600.4% |
| Citadel Advisors | Trimmed | 41,538 | 295K USD | −47.0% |
| Balyasny Asset Management | Trimmed | 30,519 | 216K USD | −95.7% |
| Marshall Wace | Exited |
What has been filed or recorded for BioAge Labs (BIOA)?
The filings we hold for BioAge Labs, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,800 shares | 58K USD notional · 0.021% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.73 USD | Revenue $0M |
| 30 Sep 2026 | Financials | Total assets | 367.6M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 346.4M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.58 USD | Revenue $2M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.52 USD | Revenue $3M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.24 USD | Revenue $9M |
| 31 Dec 2025 | Financials | Revenue | 9.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −80.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.24 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.56 USD | Revenue $2M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.60 USD | Revenue $2M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.36 USD | Revenue $1M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −6.63 USD |
What do people ask about BioAge Labs (BIOA)?
What did BioAge Labs shares close at?4.28
BioAge Labs closed at 4.28 USD on 20 Nov 2026, down 9.23% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is BioAge Labs’ market cap?196.7M
BioAge Labs is worth 196.7M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is BioAge Labs’ revenue?9.0M
BioAge Labs reported revenue of 9.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have BioAge Labs insiders bought or sold shares recently?
No BioAge Labs insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 30 Jun 2026 (SEC Form 4). See Insiders
Which funds own BioAge Labs?8 of 45
8 of the 45 funds we track reported a BioAge Labs position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Millennium Management and Renaissance Technologies. See Funds
When did BioAge Labs last report earnings?−0.73
BioAge Labs last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.73 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words